Biogen Inc. (BIIB)
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company's next phase of growth, Adam Meyers, head of the company's immunology and new disease areas franchise, said at Bank of America's annual healthcare conference in Las Vegas.
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.57 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.02 per share a year ago.
Biogen cuts annual profit forecast on acquisition-related charges
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter earnings beat expectations on better-than-estimated sales of its Alzheimer's and newer rare-disease treatments.
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
Biogen upgraded by UBS on ‘slew of pipeline catalysts' going into 2027
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy' from ‘Neutral' by UBS analysts, who also raised their price target to $225 from $185, citing growing confidence in a series of clinical and commercial catalysts expected over the next 12 to 15 months. Shares of Biogen traded hands at about $190 on Wednesday afternoon.
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?
Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his price target to $250 from $200.
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.
